相似文献
1
Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.
Antimicrob Agents Chemother. 1998 Apr;42(4):991-2. doi: 10.1128/AAC.42.4.991.
2
Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Antimicrob Agents Chemother. 1999 Oct;43(10):2372-5. doi: 10.1128/AAC.43.10.2372.
3
Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.
Antimicrob Agents Chemother. 2000 Aug;44(8):2179-81. doi: 10.1128/AAC.44.8.2179-2181.2000.
4
Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.
Infection. 2000 Jan-Feb;28(1):13-20. doi: 10.1007/s150100050004.
5
Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae.
J Chemother. 2001 Oct;13(5):535-40. doi: 10.1179/joc.2001.13.5.535.
6
Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis.
J Antimicrob Chemother. 1997 Jun;39(6):781-8. doi: 10.1093/jac/39.6.781.
7
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.
Antimicrob Agents Chemother. 1999 Apr;43(4):963-5. doi: 10.1128/AAC.43.4.963.
8
Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
Chemotherapy. 2000 Sep-Oct;46(5):303-8. doi: 10.1159/000007302.
9
Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1997 Feb;41(2):478-80. doi: 10.1128/AAC.41.2.478.
10
Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 May;47(5):623-9. doi: 10.1093/jac/47.5.623.
引用本文的文献
1
Prediction of the synergistic effect of antimicrobial peptides and antimicrobial agents via supervised machine learning.
BMC Biomed Eng. 2024 Jan 17;6(1):1. doi: 10.1186/s42490-024-00075-z.
2
Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin.
Antimicrob Agents Chemother. 2003 Jan;47(1):144-7. doi: 10.1128/AAC.47.1.144-147.2003.
3
Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.
Antimicrob Agents Chemother. 2000 Aug;44(8):2179-81. doi: 10.1128/AAC.44.8.2179-2181.2000.
4
Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Antimicrob Agents Chemother. 1999 Oct;43(10):2372-5. doi: 10.1128/AAC.43.10.2372.
5
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.
Antimicrob Agents Chemother. 1999 Apr;43(4):963-5. doi: 10.1128/AAC.43.4.963.
本文引用的文献
1
Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
Antimicrob Agents Chemother. 1997 Jun;41(6):1298-300. doi: 10.1128/AAC.41.6.1298.
2
Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1997 May;41(5):1186-9. doi: 10.1128/AAC.41.5.1186.
3
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.
Antimicrob Agents Chemother. 1996 May;40(5):1208-13. doi: 10.1128/AAC.40.5.1208.
4
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6. doi: 10.1128/AAC.39.10.2210.
5
Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.
Clin Infect Dis. 1994 Feb;18(2):188-93. doi: 10.1093/clinids/18.2.188.
6
Antibiotic-resistant pneumococci.
Pediatr Clin North Am. 1995 Jun;42(3):519-37. doi: 10.1016/s0031-3955(16)38977-5.
7
Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections.
Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S18-25.
8
Appearance of resistance to beta-lactam antibiotics during therapy for Streptococcus pneumoniae meningitis.
J Pediatr. 1995 Jul;127(1):98-9. doi: 10.1016/s0022-3476(95)70264-4.
Zotero 插件